Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vaxcyte, Inc.

35.39
+0.15000.43%
Pre-market: 35.500.1100+0.31%06:59 EDT
Volume:1.94M
Turnover:69.58M
Market Cap:4.57B
PE:-9.31
High:36.71
Open:35.75
Low:34.90
Close:35.24
Loading ...

Company Profile

Company Name:
Vaxcyte, Inc.
Exchange:
NASDAQ
Establishment Date:
2013
Employees:
414
Office Location:
825 Industrial Road,Suite 300,San Carlos,California,United States
Zip Code:
94070
Fax:
- -
Introduction:
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against these emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Directors

Name
Position
Grant E. Pickering
President, Chief Executive Officer and Director
Moncef Slaoui
Chairman of the Board
Halley Gilbert
Director
Heath Lukatch
Director
Kurt von Emster
Director
Patrick Enright
Director
Patrick Heron
Director
Peter Hirth
Director
Rob Hopfner
Director
William J. Newell
Director

Shareholders

Name
Position
Grant E. Pickering
President, Chief Executive Officer and Director
Jim Wassil
Chief Operating Officer
Andrew Guggenhime
Chief Financial Officer and Chief Business Officer
Paul Sauer
Senior Vice President, Process Development and Manufacturing
Jane Wright Mitchell
General Counsel
Jeff Fairman
Vice President, Research